**[217] BIOLINERX DEVELOPING BL-8040: A CXCR4 ANTAGONIST WHICH COULD IMPROVE THE ACTIVITY OF IMMUNE CHECKPOINT INHIBITORS**

**David Malek1, Yaron Pereg1, Tomer Bahar1, 1 Biolinerx**

**Questions for Biotech/Pharma; Medical Devices and Health IT/Digital Health categories are:**

**Answers should not exceed 60** **words per question**

**Investment Rational**   
BioLineRx is a publicly-traded (NASDAQ/TASE), clinical-stage company, primarily focused on oncology and immunology. BioLineRx has a strategic collaboration with Novartis for identification and development of innovative drug candidates. BL-8040, the company’s lead asset, is a novel CXCR4 antagonist, developed for solid and hematological malignancies. BL-8040 in combination with KEYTRUDA is being developed for pancreatic cancer, in collaboration with Merck (MSD).

**Business Strategy**   
BioLineRx's close ties with research institutions and biotechnology companies, both in Israel and globally, enable access to promising early stage projects. BioLineRx in-licenses promising projects and further develops them through pre-clinical and clinical stages usually through Phase II PoC in humans. The company partners with medium and large size pharmaceutical companies to complete the clinical development and commercialization.

**Core Technology**   
BL-8040 is a best in class CXCR4 antagonist with dual anti-tumor activity. It induces directory migration of anti-tumor T-cells and selectively reduces intratumoral accumulation of immune suppressor cells. BL-8040 also directly induces CXCR4-dependent apoptosis in cancer cells. Combination of BL-8040 with immune checkpoints inhibitors can potentially expand the benefit of immunotherapy to cancer types currently resistant to immuno-oncology treatments.

**Product Profile/Pipeline**   
BL-8040 is currently undergoing multiple Phase 2 trials for the treatment of AML, stem cell mobilization and for bone marrow failure indications. BL-8040 will also be assessed in a Phase 2 study in combination with KEYTRUDA (pembrolizumab; PD1 mAb) in patients with metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer, as part of collaboration with Merck (MSD).

**What's Next?**   
BioLineRx plans to increase its immuno-oncology activity by in-licensing additional novel immunotherapy agents. In addition, BioLineRx will continue to broaden the development of BL-8040 in the field of immunotherapy by collaborating with additional pharmaceutical companies to evaluate the potential of combination immunotherapy of BL-8040 with immune checkpoints inhibitors in additional hematological and solid tumor unmet indications.